Guidelines for new preventive treatments available for HIV

2^nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

November 23-24, 2012 Hyderabad International Convention Centre, India

Radhadevi.N

Posters: Pharmaceut Reg Affairs

Abstract :

Available evidence indicates HIV-infected population promising new approach has emerged. HIV causes an infectious disease that, with the right prevention interventions delivered within a human rights framework, can be controlled and possibly even eliminated. WHO, UNAIDS and the United Nations General Assembly have called for 15 million people to be on ART by 2015. Anti Retroviral Treatment (ART) has considerable benefit, both as treatment and in preventing HIV. Preexposure prophylaxis (PrEP) is available from studies with two groups: men and transgender women who have sex with men; and serodiscordant heterosexual couples. Several human clinical trials evaluating the efficacy of daily regimens of the HIV reversetranscriptase (RT) inhibitors tenofovir disoproxil fumarate (TDF) or Truvada (TDF and emtricitabine [FTC]) are under way among high-risk populations. The results of one trial among men who have sex with men showed that daily Truvada was safe and effective, providing the first support for oral PrEP as a prevention strategy. This article summarizes Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV.

Biography :

Rajendar.M is a student of JSS College of Pharmacy, JSS University, Mysore, Karnataka, India. He has completed his B Pharm from JSS College of Pharmacy, Mysore during the year 2011. Presently he is pursuing M Pharm in Industrial pharmacy in JSS College of Pharmacy, Mysore. He has attended various National and International Conferences. His current areas of interest are Quality Assurance, Regulatory Affairs, Quality Management Systems, pharmaceutical technology and analytical method development.